GENinCode (LON:GENI) Shares Down 7.1% – What’s Next?

Shares of GENinCode Plc (LON:GENI) were down 7.1% during mid-day trading on Thursday . The company traded as low as GBX 0.86 and last traded at GBX 0.93. Approximately 3,936,327 shares traded hands during trading, a decline of 38% from the average daily volume of 6,329,568 shares. The stock had previously closed at GBX 1.

GENinCode Trading Up 4.4%

The stock has a fifty day moving average of GBX 1.08 and a 200-day moving average of GBX 1.40. The company has a market cap of £6.82 million, a PE ratio of -0.40 and a beta of 0.59. The company has a debt-to-equity ratio of 117.74, a quick ratio of 15.88 and a current ratio of 0.93.

GENinCode (LON:GENI) last released its earnings results on Monday, June 8th. The company reported GBX (2.08) earnings per share for the quarter. GENinCode had a negative return on equity of 409.40% and a negative net margin of 185.47%.The business had revenue of GBX 308 million during the quarter. Sell-side analysts anticipate that GENinCode Plc will post -7.1299999 EPS for the current fiscal year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.